Phaseline

Targets › NDUFS1

NDUFS1 (NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Metabolic and endocrine; next expected readout Mar 2027.

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor. Essential for catalysing the entry and efficient transfer of electrons within complex I. Plays a key role in the assembly and stability of complex I and participates in the association of complex I with…. (UniProt, P28331)

Open in Phaseline: the race on NDUFS1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Center for Global Health and Medicine, JapanImeglimin
Mitochondrial complex I modulator
NDUFS1Phase 4Diabetes Mellitus, Type 2Mar 2027

Conditions

Diabetes Mellitus, Type 2 (1)

Modalities

small molecule (1)

Companies

National Center for Global Health and Medicine, Japan (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.